RT Journal Article
T1 A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
A1 Martinez-Trufero, Javier
A1 De-Sande-Gonzalez, Luis Miguel
A1 Luna, Pablo
A1 Martin-Broto, Javier
A1 Alvarez, Rosa
A1 Marquina, Gloria
A1 Diaz-Beveridge, Roberto
A1 Poveda, Andres
A1 Cano, Juana Maria
A1 Cruz-Jurado, Josefina
A1 Lopez-Pousa, Antonio
A1 Vaz-Salgado, Maria Angeles
A1 Valverde-Morales, Claudia M.
A1 Sevilla, Isabel
A1 Martinez-Garcia, Jeronimo
A1 Rubio-Casadevall, Jordi
A1 De Juan, Ana
A1 Carrasco, Juan Antonio
A1 Moura, David S.
A1 Gurruchaga-Sotes, Ibon
A1 Gutiérrez, Antonio
K1 Trabectedin
K1 Sarcoma
K1 Growth modulation index
K1 Prognostic score
K1 L-sarcoma
K1 GEISTRA
K1 Spain
K1 Advanced soft tissue sarcomas
K1 Trabectedina
K1 Pronóstico
K1 Liposarcoma
K1 Leiomiosarcoma
K1 España
AB The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.
PB MDPI
YR 2021
FD 2021-02-14
LK http://hdl.handle.net/10668/4498
UL http://hdl.handle.net/10668/4498
LA en
NO Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, et al. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers. 2021 Feb 14;13(4):792
DS RISalud
RD Apr 5, 2025